Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial. Contact Us. Contact Us. ... “We confirmed this response with a second scan, ...

Non-small cell lung cancer (NSCLC) is the most common kind of lung cancer, making up about 80 to 85 percent of all cases, according to the American Cancer Society (ACS). It’s referred to as ...

Adventist Health Ukiah Valley recently unveiled its new PET/CT machine, which will offer faster results and peace of mind for ...

Non–small cell lung cancer (NSCLC) represents approximately 87% of all lung cancer cases, and in the United States and Europe, approximately up to 15% of patients with NSCLC have an EGFR mutation. For ...

Non-small cell lung cancer (NSCLC) accounts for 85% of all new lung cancer cases in the world each year, of which 50% are in the elderly. At present, chemotherapy and radiotherapy are still the main ...

Background: While immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer (NSCLC) treatment, predicting immune-related adverse events (irAEs) remains challenging. We ...

More information: Yuanning Zheng et al, Single-cell multimodal analysis reveals tumor microenvironment predictive of treatment response in non–small cell lung cancer, Science Advances (2025 ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...